Efficacy and safety of RTS,S/AS01 malaria vaccine with or without a booster dose in infants and children in Africa: final results of a phase 3, individually randomised, controlled trial

by RTS,S Clinical Trials Partnership
The Lancet – Online first, April 23, 2015

15 pp. 849 kB:

The efficacy and safety of the RTS,S/AS01 candidate malaria vaccine during 18 months of follow-up have been published previously. Herein, the authors report the final results from the same trial, including the efficacy of a booster dose. They conclude that RTS,S/AS01 prevented a substantial number of cases of clinical malaria over a 3-4 year period in young infants and children when administered with or without a booster dose. Efficacy was enhanced by the administration of a booster dose in both age categories. Thus, the vaccine has the potential to make a substantial contribution to malaria control when used in combination with other effective control measures, especially in areas of high transmission.

(Visited 233 times, 1 visits today)
This entry was posted in General, Malaria. Bookmark the permalink.